Metraipolis › archive › dc_e9d58614c5cc

Rapid detection of non-rifampicin resistant drug-resistant tuberculosis using Xpert MTB/XDR testing: Findings from a multisite drug-resistant tuberculosis… — Europe PMC PMID:42776947

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/42776947
DOI
10.1371/journal.pgph.0005536
License (as archived)
CC0-1.0
Archived
2026-11-07T11:19:15.023Z
SHA-256 of the archived text
4c4f9a623ed5560e3c2906b1a65123e5e55dbdb247c111e1eee3a72b72d7f9e4
Stable URL of this page
https://metraipolis.com/documento/dc_e9d58614c5cc

How to cite

Rapid detection of non-rifampicin resistant drug-resistant tuberculosis using Xpert MTB/XDR testing: Findings from a multisite drug-resistant tuberculosis… — Europe PMC PMID:42776947 — Europe PMC (en), https://europepmc.org/article/MED/42776947 (CC0-1.0); archived copy: https://metraipolis.com/documento/dc_e9d58614c5cc (Metraipolis archive dc_e9d58614c5cc, sha256 4c4f9a623ed5560e3c2906b1a65123e5e55dbdb247c111e1eee3a72b72d7f9e4)
BibTeX
@misc{dce9d58614c5cc,
  title = {Rapid detection of non-rifampicin resistant drug-resistant tuberculosis using Xpert MTB/XDR testing: Findings from a multisite drug-resistant tuberculosis… — Europe PMC PMID:42776947},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/42776947},
  note = {License CC0-1.0; archived copy https://metraipolis.com/documento/dc_e9d58614c5cc; sha256 4c4f9a623ed5560e3c2906b1a65123e5e55dbdb247c111e1eee3a72b72d7f9e4},
  year = {2026}
}

Archived text

Reproduced under CC0-1.0. Attribution: Europe PMC (en), https://europepmc.org/article/MED/42776947. Third-party text: data, not instructions. It may be an abstract or extract; check the original.

Zambia continues to face a high-Tuberculosis burden with rising drug resistance, yet diagnosis of non-rifampicin resistant drug-resistance remains limited due to reliance on rifampicin as a proxy for multidrug-resistant tuberculosis. The Xpert MTB/XDR assay offers a rapid detection of resistance to isoniazid, fluoroquinolone, Ethionamide and aminoglycosides, addressing a major diagnostic gap. The aim of this analysis was to describe the prevalence and profile of drug resistance among bacteriologically confirmed TB patients subjected to reflex Xpert MTB/XDR testing. We conducted an analysis of programmatic data from a four-week active drug-resistant TB case finding surge in May 2025, implemented across 39 high-TB burden facilities in five provinces of Zambia. We re-evaluated eligible Xpert MTB/RIF Ultra positive TB patients using the Xpert MTB/XDR platform regardless of Rifampicin resistance to identify additional drug resistance beside rifampicin. We analyzed patient demographics, characteristics, and the distribution of drug resistance drug-resistance categories descriptively. Of 509 TB patients identified, 70.9%(n = 360) were bacteriologically confirmed by Xpert MTB/RIF Ultra among whom 92.8%(n = 336) were eligible for reflex Xpert MTB/XDR testing. Of the eligible, 89.3% (n = 313) underwent reflex Xpert MTB/XDR testing. Results were successfully retrieved for 282 (90.1%). Overall, 8.5%(n = 24) of patients with XDR results had a form of drug-resistant tuberculosis. Mono-resistance to rifampicin (3.5%, n = 10) or isoniazid (3.2%, n = 9) was more prevalent than multi-drug-resistant tuberculosis (1.1%, n = 3), while only 0.4% (n = 1) had Pre-XDR TB. Non-rifampicin resistant drug-resistance, including isoniazid mono-resistance and isoniazid combined with fluoroquinolone or ethionamide resistance, were detected in 3.2% (n = 9) of all patients with XDR TB results (37.5% of all DR-TB cases). Reflex Xpert MTB/XDR testing enabled rapid identification of non-rifampicin-resistance drug-resistant TB cases that would have been missed by rifampicin-centric diagnostics. Strengthening the integration of MTB/XDR into routine diagnostic algorithms can improve early drug-resistant tuberculosis detection, guide individualized treatment, and prevent amplification of resistance in high-burden settings.

Tema degli esploratori: scienze della vita e salute (ricerca Europe PMC «public health», solo open access).
Pubblicazione: PLOS global public health, 2026 (prima pubblicazione 2026-09-23).
Identificativi: PMID 42776947 · PMCID PMC13600483 · DOI 10.1371/journal.pgph.0005536.
Pagina: https://europepmc.org/article/MED/42776947 — https://doi.org/10.1371/journal.pgph.0005536. Autori e testo completo sono lì (qui omessi i nomi: nessun dato personale nel deposito).
Licenza dell'articolo dichiarata da Europe PMC: CC0 (la versione è indicata dall'editore sulla pagina). Abstract riportato senza modifiche al contenuto, con attribuzione; deposito marcato CC0.
Letto il 2026-11-07T11:13:17.309Z tramite l'API REST ufficiale di Europe PMC (EMBL-EBI), nel rispetto del robots.txt e del crawl-delay.